Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress

Nuclear Medicine and Biology

Volumn 34, Issue 6, 2007, Pages 667-679

  Logan, Jean ^a   Wang, Gene jack ^a   Telang, Frank ^a   Fowler, Joanna S ^a   Alexoff, David ^a   Zabroski, John ^a   Jayne, Millard ^a   Hubbard, Barbara ^a   King, Payton ^a   Carter, Pauline ^a   Shea, Colleen ^a   Xu, Youwen ^a   Muench, Lisa ^a   Schlyer, David ^a   Learned Coughlin, Susan ^b   Cosson, Valerie ^b   Volkow, Nora D ^c   Ding, Yu shin ^d  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

11C (S,S) MRB; Atomoxetine; Norepinephrine transporter; PET

Indexed keywords

ATOMOXETINE; NORADRENALIN TRANSPORTER; REBOXETINE;

ADULT; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; HUMAN; IMAGE ANALYSIS; LOCUS CERULEUS; MALE; MESENCEPHALON; NORADRENALIN UPTAKE; POSITRON EMISSION TOMOGRAPHY; RECEPTOR AFFINITY; RECEPTOR DENSITY; THALAMUS;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ALGORITHMS; BRAIN; CARBON RADIOISOTOPES; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MORPHOLINES; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; PROPYLAMINES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 34547851802     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.03.013     Document Type: Article

References (41)

1. Zahniser N., and Doolen S. Chronic and acute regulation of Na+/Cl--dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol Ther 92 (2001) 21-55
2. Klimek V., Stockmeier C., Overholser J., Meltzer H.Y., Kalka S., Dilley G., et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 17 (1997) 8451-8458
3. Bymaster F., Katner J., Nelson D., Hemrick-Luecke S., Threlkeld P., Heiligenstein J., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2002) 699-711
4. Remy P., Doder M., Lees A., Turjanski N., and Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 (2005) 1314-1322
5. Srinivasan J., and Schmidt W. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur J Neurosci 17 (2003) 2586-2592
6. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., and Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275 (1983) 321-328
7. Riederer P., Birkmayer W., Seemann D., and Wuketich S. Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome. J Neural Transm 41 (1977) 241-251
8. Herrmann N., Lanctot K.L., and Khan L.R. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 16 (2004) 261-276
9. Aston-Jones G., and Cohen J. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 28 (2005) 403-450
10. Aston-Jones G., Rajkowski J., Kubiak P., and Alexinsky T. Locus coeruleus neurons in monkey are selectively activated by attended cues in a vigilance task. J Neurosci 14 (1994) 4467-4480
11. Tejani-Butt S., Brunswick D., and Frazer A. [3H]Nisoxetine: a new radioligand for norepinephrine uptake sites in brain. Eur J Pharmacol 191 (1990) 239-243
12. Charnay Y., Leger L., Vallet P., Hof P., Jouvet M., and Bouras C. [3H]Nisoxetine binding sites in the cat brain: an autoradiographic study. Neuroscience 69 (1995) 259-270
13. Haka M., and Kilbourn M. Synthesis and regional mouse brain distribution of [11C]nisoxetine, a norepinephrine uptake inhibitor. Int J Rad Appl Instrum B 16 (1989) 771-774
14. Kung M., Choi S., Hou C., Zhuang Z., Foulon C., and Kung H. Selective binding of 2-[125I]iodo-nisoxetine to norepinephrine transporters in the brain. Nucl Med Biol 31 (2004) 533-541
15. Kiyono Y., Kanegawa N., Kawashima H., Kitamura Y., Iida Y., and Saji H. Evaluation of radioiodinated (R)-N-methyl-3-(2-iodophenoxy)-3-phenylpropanamine as a ligand for brain norepinephrine transporter imaging. Nucl Med Biol 31 (2004) 147-153
16. Ding Y., Lin K., Logan J., Benveniste H., and Carter P. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine. J Neurochem 94 (2005) 337-351
17. Logan J., Ding Y., Lin K., Pareto D., Fowler J., and Biegon A. Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region. Nucl Med Biol 32 (2005) 531-542
18. Biegon A., and Rainbow T. Localization and characterization of [3H]desmethylimipramine binding sites in rat brain by quantitative autoradiography. J Neurosci 3 (1983) 1069-1076
19. Lee C., Javitch J., and Snyder S. Characterization of [3H]desipramine binding associated with neuronal norepinephrine uptake sites in rat brain membranes. J Neurosci 2 (1982) 1515-1525
20. Gross-Isseroff R., Israeli M., and Biegon A. Autoradiographic analysis of [3H]desmethylimipramine binding in the human brain postmortem. Brain Res 456 (1988) 120-126
21. Schou M., Sovago J., Pike V., Gulyas B., Bogeso K., Farde L., et al. Synthesis and positron emission tomography evaluation of three norepinephrine transporter radioligands: [C-11]desipramine, [C-11]talopram and [C-11]talsupram. Mol Imaging Biol 8 (2006) 1-8
22. Van Dort M., Kim J., Tluczek L., and Wieland D. Synthesis of 11C-labeled desipramine and its metabolite 2-hydroxydesipramine: potential radiotracers for PET studies of the norepinephrine transporter. Nucl Med Biol 24 (1997) 707-711
23. Wong E., Sonders M., Amara S., Tinholt P., Piercey M., Hoffmann W., et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47 (2000) 818-829
24. Schou M., Halldin C., Sovago J., Pike V., Gulyas B., Mozley P., et al. Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER. Nucl Med Biol 30 (2003) 707-714
25. Wilson A., Johnson D., Mozley D., Hussey D., Ginovart N., Nobrega J., et al. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol 30 (2003) 85-92
26. Ding Y., Lin K., Garza V., Carter P., Alexoff D., Logan J., et al. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse 50 (2003) 345-352
27. Andree B., Seneca N., Schou M., Mozley P., Potter W., Farde L., et al. [11C]MeNER human PET study: high occupancy of the central norepinephrine transporter induced by reboxetine at clinical doses. J Nucl Med (Suppl) 45 (2004) 68P
28. Schou M., Halldin C., Sovago J., Pike V., Hall H., Gulyas B., et al. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 53 (2004) 57-67
29. Lin K., Ding Y., Kim S., and Kil K. Synthesis, enantiomeric resolution, F-18 labeling and biodistribution of reboxetine analogs: promising radioligands for imaging the norepinephrine transporter with positron emission tomography. Nucl Med Biol 32 (2005) 415-422
30. Seneca N., Gulyas B., Varrone A., Schou M., Airaksinen A., Tauscher J., et al. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2. Psychopharmacology (Berl) 188 (2006) 119-127
31. Lin K., and Ding Y. Synthesis, enantiomeric resolution, and selective C-11 methylation of a highly selective radioligand for imaging the norepinephrine transporter with positron emission tomography. Chirality 16 (2004) 475-481
32. Talairach J., and Tournoux P. Co-planar stereotaxic atlas of the human brain (1988), Georg Thieme Verlag, Stuttgart
33. Feng D., Huang S.-C., Wang Z., and Ho D. An unbiased parametric imaging algorithm for nonuniformly sampled biomedical system parameter estimation. IEEE Trans Med Imaging 15 (1996) 512-518
34. Logan J., Fowler J., Ding Y., Franceschi D., Wang G., Volkow N., et al. Strategy for the formation of parametric images under conditions of low injected radioactivity applied to PET studies with the irreversible monoamine oxidase A tracers [11C]clorgyline and deuterium-substituted [11C]clorgyline. J Cereb Blood Flow Metab 22 (2002) 1367-1376
35. Ordway G.A., Stockmeier C.A., Cason G.W., and Klimek V. Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. J Neurosci 17 (1997) 1710-1719
36. Schou M., Halldin C., Pike V., Mozley P., Dobson D., Innis R., et al. Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2. Eur Neuropsychopharmacol 15 (2005) 517-520
37. Michelson D., Faries D., Wernicke J., Kelsey D., Kendrick K., Sallee F.R., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108 (2001) e83
38. Michelson D., Allen A.J., Busner J., Casat C., Dunn D., Kratochvil C., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159 (2002) 1896-1901
39. Logan J., Fowler J., Volkow N., Wolf A., Dewey S., Schlyer D., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10 (1990) 740-747
40. Smith H., Beveridge T., and Porrino L. Distribution of norepinephrine transporters in the non-human primate brain. Neuroscience 138 (2006) 703-714
41. Elsworth J., Deutch A., Redmond D., Sladek J., and Roth R. MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulate cortex of the primate. Neurosci Lett 114 (1990) 316-322